Cocrystal Pharma (NASDAQ:COCP) Trading Down 5.6% – Time to Sell?

Cocrystal Pharma, Inc. (NASDAQ:COCP)’s stock price fell 5.6% during mid-day trading on Monday . The company traded as low as $1.17 and last traded at $1.17. 23,073 shares changed hands during trading, a decline of 59% from the average session volume of 56,429 shares. The stock had previously closed at $1.24.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Cocrystal Pharma Stock Performance

The company has a market capitalization of $22.53 million, a price-to-earnings ratio of -1.54 and a beta of 1.48. The firm has a fifty day moving average price of $1.05 and a 200-day moving average price of $1.13.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.06). The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.10 million. On average, sell-side analysts forecast that Cocrystal Pharma, Inc. will post -0.65 EPS for the current fiscal year.

Institutional Trading of Cocrystal Pharma

An institutional investor recently bought a new stake in Cocrystal Pharma stock. T3 Companies LLC purchased a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned approximately 0.38% of Cocrystal Pharma at the end of the most recent quarter. 6.72% of the stock is currently owned by institutional investors and hedge funds.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.